 Home > Encyclopedia > Atrasentan

Atrasentan

Atrasentan structure

CAS No:
173937-91-2
Formula:
C29H38N2O6
Chemical Name:
Atrasentan
Synonyms:
3-Pyrrolidinecarboxylic acid,4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-,(2R,3R,4S)-;3-Pyrrolidinecarboxylic acid,4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-,[2R-(2α,3β,4α)]-;(2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid;(+)-A 127722;ABT 627;Atrasentan;A 147627;Altrasentan;(2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid
Categories:
Pharmaceutical Intermediates > Bulk Drug Intermediates

Description

Atrasentan is an endothelin receptor antagonist with IC50 of 0.0551 nM for ETA.

Atrasentan is a member of pyrrolidines.|Atrasentan is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called endothelin-1 protein receptor antagonists. It is a novel, selective endothelin A receptor antagonist (SERA).|A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.

Atrasentan Basic Attributes

Molecular Weight：

510.62

Exact Mass：

510.62

UNII：

V6D7VK2215

NSC Number：

720763

Characteristics

PSA：

88.5

XLogP3：

4.63190

Density：

1.188±0.06 g/cm3(Predicted)

Melting Point：

122-124°

Boiling Point：

659.4±55.0 °C(Predicted)

Flash Point：

352.6ºC

Vapor Pressure：

2.76E-18mmHg at 25°C

Safety Information

Precautionary statement(s)：

P201, P202, P264, P270, P280, P281, P301+P312, P302+P352, P305+P351+P338, P308+P313, P321, P330, P332+P313, P337+P313, P362, P405, P501

Hazard Statements：

H302

GHS Classification：

|Danger|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P264, P270, P280, P281, P301+P312, P302+P352, P305+P351+P338, P308+P313, P321, P330, P332+P313, P337+P313, P362, P405, and P501|Aggregated GHS information provided by 48 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

Drug Indication：

Investigated for use/treatment in prostate cancer and cancer/tumors (unspecified).

MeSH：

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN A RECECPTORS. (See all compounds classified as Endothelin A Receptor Antagonists.)|Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

MeSH Entry Terms：

(11C)ABT-627

Atrasentan Use and Manufacturing

Palliative treatment of bone pain due to metastatic prostate cancer and disease progression (endothelin (ETA) receptor antagonist).

Computed Properties

Molecular Weight:510.6
XLogP3:2.4
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:7
Rotatable Bond Count:12
Exact Mass:510.27298694
Monoisotopic Mass:510.27298694
Topological Polar Surface Area:88.5
Heavy Atom Count:37
Complexity:734
Defined Atom Stereocenter Count:3
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of Atrasentan

Xi'an Horlden Bio-Tech Co., Ltd Contact Supplier

CN
3 YRS

Business licensed

Trader Supplier of Chemical,Intermediate,5-amino-1mq,SLU-PP332,Tirzepatide,Peptide,KY19382,5-deazaflavin,Dihexa,Urolithin A

Factory supply Pure 99% A-147627 Atrasentan raw powder CAS 173937-91-2

CAS No.: 173937-91-2

Grade: Pharmaceutical Grade

Content: 99%

Inquiry